Date published: 2026-5-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

TM Inhibitors

TM inhibitors, short for Transmembrane Inhibitors, represent a diverse and important category of chemical compounds that primarily target cellular processes involving the transmembrane proteins. These inhibitors exert their effects by modulating the function of transmembrane proteins, which are integral components of the cell membrane responsible for a wide array of biological functions, such as signal transduction, ion transport, and cell adhesion. Transmembrane proteins span the lipid bilayer of the cell membrane, with regions embedded within the hydrophobic core and portions extending into the extracellular and intracellular spaces. TM inhibitors are specifically designed to disrupt or regulate the activity of these proteins, thus influencing critical cellular functions.

TM inhibitors encompass a broad range of chemical structures and mechanisms of action. Some TM inhibitors function by binding to specific transmembrane proteins and altering their conformation, preventing them from carrying out their normal functions. Others may interfere with the assembly or trafficking of transmembrane proteins within the cell, disrupting their localization and function. Additionally, certain TM inhibitors can modulate the permeability of the cell membrane itself, affecting the transport of ions, nutrients, or other molecules across the lipid bilayer. The diverse nature of TM inhibitors allows for their application in various research contexts, such as cell biology, molecular pharmacology, and drug discovery, where they serve as invaluable tools for elucidating the roles of transmembrane proteins in cellular processes.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits the BCR-ABL kinase, blocking tyrosine phosphorylation and signaling in chronic myeloid leukemia cells.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Targets the epidermal growth factor receptor (EGFR), disrupting downstream signaling pathways in cancer cells.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Blocks EGFR kinase activity, hindering proliferation and survival of cancer cells.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple kinases, including RAF and VEGFR, disrupting cell proliferation and angiogenesis in cancer.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Targets multiple receptor tyrosine kinases, including VEGFR and PDGFR, inhibiting angiogenesis and tumor growth.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Blocks BCR-ABL and SRC kinases, impeding the growth of leukemia cells and other malignancies.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Inhibits both EGFR and HER2 tyrosine kinases, interfering with the growth of HER2-positive breast cancer cells.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

Targets BCR-ABL kinase, preventing tyrosine phosphorylation and the proliferation of leukemia cells.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$175.00
$983.00
2
(1)

Blocks BCR-ABL and other tyrosine kinases, offering therapeutic options for resistant forms of leukemia.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Inhibits VEGFR, EGFR, and RET kinases, impacting angiogenesis and signaling in thyroid cancer.